Precision Medicine & Nanotechnology

Personalized Cancer Treatment

Combining computational oncology biology models to simulate individual patient drug responses and optimize therapeutics.

Explore the Research Methodology Meet the Researcher
Dr. Afsaneh Mennati, postdoctoral researcher in Pharmaceutical Nanotechnology, working with a microscope and micropipette in a research laboratory for nanoparticle formulation and siRNA delivery targeting breast cancer therapy

Dr. Afsaneh Mennati

Researcher

Download Curriculum Vitae (PDF)
Leading Nanomedicine Researcher

Developing Advanced Nanocarriers for Target-Specific Cancer Therapeutics

Dr. Afsaneh Mennati is a researcher in Pharmaceutical Nanotechnology, specializing in the formulation of nanoparticles and target-specific siRNA delivery. Her cutting-edge research targets malignant breast cancer pathways, achieving gene silencing with minimized standard cytotoxic effects.

6+ ISI Publications
5+ Registered Protocols
siRNA Delivery Lipid Nanoparticles (LNPs) Breast Cancer Research Hybrid Polymer Synthesis
Animated Biological Simulation

The Journey of a Tumor-Suppressor Gene Nanocarrier into Cancer Cells

An automated visualization of hybrid nanocarriers delivering tumor-suppressor genes and siRNA into cancer cells, silencing driver oncogenes across three engineered stages.

01

Polymer Core Formulation

Therapeutic siRNA chains are loaded into the biodegradable polymer core, surrounded by a lipid bilayer to prevent degradation in physiological fluids.

02

Active Receptor Targeting

Targeting ligands on the nanoparticle surface bind specifically to HER2 receptors overexpressed on breast cancer cells, triggering receptor-mediated endocytosis.

03

Oncogene Silencing & Apoptosis

Inside the cell, the carrier degrades, releasing siRNA to slice target oncogene mRNA. This terminates cell proliferation and induces cell apoptosis.

Research Methodology — Not a Clinical Service

Cancer treatment simulation process

Our lab's research framework for analyzing de-identified genomic datasets — obtained exclusively through formal academic collaborations and research-ethics approvals — and translating them into computational drug-delivery simulation models. This describes a research methodology, published in peer-reviewed literature, not a diagnostic or treatment service offered to patients.

Important: The following describes our lab's research methodology, conducted exclusively within academic collaborations using de-identified data and under research-ethics (IRB) approval. This page does not offer diagnostic services, treatment advice, or a substitute for a treating physician's judgment.
1

Research Genomic Dataset Acquisition

Under formal research collaboration agreements and IRB/ethics approval, de-identified genomic sequencing datasets are obtained from partner institutions and prepared for computational analysis.

2

Computational Simulation Modeling for Target Receptor Identification

Developing digital simulation models based on the molecular profiles within research datasets, to identify patterns of targetable receptors and driver oncogenes for scientific study.

3

Computational Analysis of Compound Efficacy & Synergy

Computationally evaluating the modeled therapeutic response of drug compounds and their combinatorial synergy against studied genetic patterns, as part of drug-resistance research projects — this analysis does not substitute for a treating physician's judgment or clinical decision-making.

4

Research Findings Dissemination

Results of computational simulations — including modeled oncogene-inhibition rates and theoretical compound efficacy — are disseminated through peer-reviewed publications and shared research reports with partner institutions.

Scientific Career & Research Background

The Scientific Journey of Dr. Afsaneh Mennati

2009 — Present

A curated overview of the academic trajectory, key discoveries, research projects and honors of Dr. Afsaneh Mennati in nanomedicine, siRNA gene therapy and personalized cancer biosimulation.

2022 — 2025

First Postdoctoral Researcher, Qazvin University of Medical Sciences (QUMS)

Leading the design of nanocarriers for targeted siRNA and tumor-suppressor gene delivery in aggressive breast cancer models.

Ph.D.

Ph.D. in Pharmaceutical Nanotechnology

Synthesis and optimization of mPEG-PCL/DDAB hybrid nanoparticles for co-delivery of siRNA and anti-cancer agents to MCF-7 breast cancer cells.

Breakthrough

World-First Silencing of > 90% of Breast-Cancer-Driver Genes

A novel anti-breast-cancer formulation that, for the first time worldwide, silenced more than 90% of the driver oncogenes involved in breast cancer.

Research Focus

Research in Genomics-Driven Personalized Cancer Therapy

Developing research frameworks for modeling drug efficacy based on genomic data — integrating computational cancer biology models for theoretical drug-response prediction, published through academic studies.

Publications

6+ ISI Publications in Q1 Journals

Published in International Journal of Biological Macromolecules, Journal of Drug Delivery Science and Technology, American Journal of Cancer Research and Advanced Pharmaceutical Bulletin.

Media & Impact

Featured by INSF, IRNA, ISNA & the Vice Presidency for Science & Technology

Interviews with national scientific outlets on smart nanocarriers engineered to halt cancer growth.

Global Partnership Call 2026

Join the Global Oncology Research Network

This portal serves as a launchpad for future precision-oncology research projects — exclusively for scientific and academic collaboration, not for diagnostic or treatment services to patients. We invite universities, research laboratories, and international researchers to collaborate on hybrid nanocarrier engineering and computational biosimulation frameworks.

Initiate Collaboration Inquiry
In the Media

Interviews & Press Coverage of Dr. Mennati’s Research

Selected national press coverage of Dr. Mennati’s breakthroughs in siRNA-based breast cancer nanotherapy and postdoctoral research.

Scientific Credibility

Dr. Mennati's Publications Cited as a Reference in Wikipedia

Dr. Afsaneh Mennati's peer-reviewed findings have been reviewed by Wikipedia editors and accepted as a cited scientific reference in the following articles.

Academic Footprint

Featured Publications

View All Publications
Auto-updated · Twice Daily

Scientific News & Cancer Research Reports

View All News →
ScienceDaily — Cancer Research

Why the same DNA damage causes cancer in some people but not others

A controlled mouse study has provided direct evidence that inherited genetics can steer how cancer begins and evolves after DNA…

 ScienceDaily — Cancer Research

CRISPR makes prostate cancer vulnerable to immunotherapy

Scientists used CRISPR to make prostate cancer cells easier for the immune system to detect and destroy. The experimental treatment…

 ScienceDaily — Cancer Research

New cancer strategy could stop tumors before resistance takes hold

Researchers are applying evolutionary theory to cancer by changing treatments before tumors have time to develop resistance. Mathematical models suggest…

 National Cancer Institute (NCI)

How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint…

Immune checkpoint inhibitors have revolutionized cancer treatment, helping people with advanced melanoma, lung cancer, bladder cancer, and other cancers live…

 ScienceDaily — Cancer Research

New molecular map reveals how the flu virus hijacks human cells

Scientists uncovered how influenza A commandeers human cells, including a surprising strategy that dissolves tiny structures in the nucleus and…

 ScienceDaily — Cancer Research

This food compound may help vaccines work better in older adults

A naturally occurring compound found in foods such as wheat germ, mushrooms, and aged cheese may help older adults build…
Scientific Collaboration

Get in Touch

For inquiries about computational biosimulation research, academic collaborations, or research mentoring.